Ozempic, Lies, and Videotape: Inside Charlie Javice's Secret Second Act in Digital Health
Why did Charlie Javice bury her ties to eMed after scamming JP Morgan? And is eMed the shadowy front for digital health's darkest players?
Welcome to AI Health Uncut, a brutally honest newsletter on AI, innovation, and the state of the healthcare market. If you’d like to sign up to receive issues over email, you can do so here.
First, a quick reminder about a couple of events I’ll be attending next month. I always look forward to meeting fellow healthcare AI enthusiasts, so if you’re at any of these, please stop by and say hello.
🔵 On October 19–21, 2025, I will be attending HLTH USA in Las Vegas, NV — as an influencer, no less (don’t ask 🙄). Use my discount code if you’d also like to attend, and save $250: “H25_POLEVIKOV”.
🔵 On October 28, 2025, I will be speaking at the Health AI Summit in Albuquerque, NM.
As you are well aware, these investigations are intense and labor-intensive. I’m a one-man operation. My Founding Members Club of (currently) 19 is what I heavily rely on for resources to conduct these kinds of thorough investigations. If you’d like to become a Founding Member of the AI Health Uncut community, you can join through this link. (Substack may ask you to enter your email first before taking you to the payment page.) You’ll be making a real impact, helping me continue to challenge the system and push for better outcomes in healthcare through AI, technology, policy, and beyond.
TL;DR:
1. Introduction – How All Dark Forces in Digital Health Converge on One Place: eMed
2. A Secret CEO in Miami: Charlie Javice’s Quiet Role at eMed
3. Picking Up Babylon’s Pieces: eMed’s Strange Deal with Ali Parsa’s Failed Unicorn
4. Burning Cash and Buying Credibility: eMed’s Money Trail and the Linda Yaccarino Gamble
5. From COVID Kits to Ozempic: eMed’s Shape-Shifting Pivots
6. Rogue’s Gallery: Michael Ferro’s Oversight and Digital Health’s Hall of Shame
7. Conclusion - Is eMed Yet Another Digital Health Failure in the Making?
1. Introduction – How All Dark Forces in Digital Health Converge on One Place: eMed
What I’m confiding in you here isn’t in the hundreds of litigation pages filed by the DOJ and SEC in the Charlie Javice and Olivier Amar indictment case. Namely, how they slipped into the digital health industry while scamming JPMorgan. It’s a bizarre story where all roads lead to one glossy façade — a shady digital health outfit called eMed.
With Charlie Javice and her associate Olivier Amar set to be sentenced next Monday, September 29, 2025 — both facing several years in prison for defrauding JPMorgan out of $175M with inflated customer numbers — I dug into Javice’s ties to the digital health industry. And surprise, surprise: all dark roads in digital health seem to lead back to one company: eMed. The same chameleon outfit that was peddling COVID test kits when that was the hot trade, now reinvented as a GLP-1 reseller because that’s where the wind is blowing.
In an industry already scarred by Theranos, Health IQ, and other fraud cases, a new exposé is unfolding at the crossroads of failed digital health startups, lax oversight, and high-profile schemers. At the center is eMed, a Miami-based telehealth startup that rose to prominence selling at-home COVID-19 test kits, and has been effectively controlled by its founder and key investor, Michael Ferro. eMed has quietly entangled itself with Charlie Javice – the 30-under-30 wunderkind-turned-indicted fraudster behind college-aid startup Frank – and even picked up the remnants of Babylon Health, the once-$4.2B U.K. unicorn reduced to rubble under Ali Parsa.
This investigation, timed ahead of Javice’s upcoming sentencing on federal fraud charges, uncovers how eMed became a nexus for shadowy characters and questionable deals in digital health.
I will explore why Javice and her Frank lieutenant Olivier Amar were stealthily working at eMed in 2022, even as Javice’s $175M Frank sale to JPMorgan unraveled into fraud, and why their roles there had to be kept “off the books.” I ask whether regulators like the U.S. Department of Justice or SEC knew about Javice’s secret role – and what legal/ethical implications it raises.
Next, I explore eMed’s bargain-bin acquisition of Babylon’s “GP at Hand” UK assets, despite the public discrediting of Parsa’s AI-driven health tech. Who brokered that fire-sale deal, and what motivations underpinned it?
Finally, I scrutinize how eMed – reportedly hemorrhaging cash – could afford to hire former X (Twitter) CEO Linda Yaccarino as its new CEO. Follow the money: from government contracts to behind-the-scenes investor maneuvers (hello, Michael Ferro), to see what’s propping up this venture.
The tone here is deliberately fiery – think “The Madoff of Digital Health”, but with facts front and center. You’ll find whistleblower testimony, court filings, and credible reports cited throughout. We’ll also chart eMed’s own pivot timeline – from COVID test kits, to an “urgent care in a box” vision, to the current craze of reselling GLP-1 weight-loss drugs like Ozempic. Along the way, we reveal eMed’s financial and regulatory trail, its revolving-door leadership, and the influential role of Michael Ferro (eMed’s founder and a controversial media magnate) in steering capital and strategy. And we’ll connect the dots to other digital health failures, illuminating a troubling pattern of hype, hubris, and scant oversight.
Buckle up for a spicy ride through the underbelly of digital health – where eMed and Charlie Javice’s stories converge in a cautionary tale of innovation and deception.
2. A Secret CEO in Miami: Charlie Javice’s Quiet Role at eMed
Keep reading with a 7-day free trial
Subscribe to AI Health Uncut to keep reading this post and get 7 days of free access to the full post archives.